Perigon Wealth Management LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO – Get Rating) by 3.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,603 shares of the company’s stock after buying an additional 80 shares during the quarter. Perigon Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $259,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the stock. Cubist Systematic Strategies LLC boosted its holdings in shares of Novo Nordisk A/S by 184.4% during the second quarter. Cubist Systematic Strategies LLC now owns 73,193 shares of the company’s stock worth $8,156,000 after purchasing an additional 47,455 shares during the last quarter. Keybank National Association OH boosted its holdings in shares of Novo Nordisk A/S by 11.1% during the third quarter. Keybank National Association OH now owns 27,511 shares of the company’s stock worth $2,741,000 after purchasing an additional 2,755 shares during the last quarter. Old North State Trust LLC acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $41,000. Canvas Wealth Advisors LLC acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $211,000. Finally, Asset Dedication LLC acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth $96,000. Institutional investors and hedge funds own 6.09% of the company’s stock.
Novo Nordisk A/S Trading Up 0.4 %
NYSE:NVO opened at $139.44 on Friday. The business’s 50-day moving average is $139.97 and its two-hundred day moving average is $123.57. The company has a debt-to-equity ratio of 0.29, a current ratio of 0.89 and a quick ratio of 0.69. Novo Nordisk A/S has a 12 month low of $95.02 and a 12 month high of $145.94. The firm has a market capitalization of $315.55 billion, a PE ratio of 40.18, a price-to-earnings-growth ratio of 1.49 and a beta of 0.47.
Novo Nordisk A/S Increases Dividend
Analysts Set New Price Targets
Several research firms have recently issued reports on NVO. Cowen raised their price objective on Novo Nordisk A/S from $130.00 to $145.00 in a report on Monday, December 12th. JPMorgan Chase & Co. increased their target price on Novo Nordisk A/S from 925.00 to 1,100.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 3rd. Cowen increased their target price on Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. Finally, StockNews.com initiated coverage on Novo Nordisk A/S in a research report on Thursday. They issued a “strong-buy” rating on the stock. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $697.78.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.
- Get a free copy of the StockNews.com research report on Novo Nordisk A/S (NVO)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.